Human Ghrelin as an Effective Mitigator of Acute Radiation Injury

人类生长素释放肽作为急性辐射损伤的有效缓解剂

基本信息

  • 批准号:
    9141294
  • 负责人:
  • 金额:
    $ 98.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-20 至 2019-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): This SBIR Phase II proposal is intended to further develop human ghrelin as a radiation medical countermeasure (MCM) to be approved by the FDA in the future. The risks of nuclear terrorism and nuclear power plant leaks still remain high, both of which can cause acute radiation injury on a large scale. Currently, there are limited drugs available to treat acute radiation syndrome (ARS). Human ghrelin is a 28-amino acid peptide hormone with broad effects on various body systems, including the endocrine, gastrointestinal (GI), cardiovascular, and immune systems. In our completed SBIR Phase I project, we have exposed rats and mice to total body irradiation (TBI) and demonstrated that subcutaneous administration of human ghrelin for 6 days, starting at 24 h post-TBI, significantly increased their survival rates and reduced their body weight loss. We further demonstrated, in the rat, that treatment with human ghrelin improved intestinal integrity and reduced gut apoptosis and permeability. Human ghrelin can be synthesized in large quantity for mass emergency needs. Moreover, human ghrelin has been tested in several clinical trials for other disease indications with an excellent safety profile. Based on our positive Phase I results, we hypothesize that human ghrelin can be developed as an effective post-exposure mitigator for acute radiation injury. In this proposal, we will use the mouse model of radiation injury to identiy the dose modification factor (DMF) of human ghrelin to treat GI-ARS and hematopoietic ARS (H- ARS). We will also examine human ghrelin's effect to attenuate hematopoietic and GI damages. In addition, we will conduct an exploratory study in non-human primates (NHP) to evaluate the effect of human ghrelin treatment on the GI and hematology response to radiation exposure. These proposed studies should provide crucial information on the efficacy of human ghrelin as a novel radiation MCM primarily targeting GI-ARS. Our ultimate goal is to obtain the FDA approval to use human ghrelin as a safe and effective treatment for people with acute radiation injury after a radiation emergency.
 描述(由申请人提供):该 SBIR II 期提案旨在进一步开发人类生长素释放肽,作为未来 FDA 批准的辐射医学对策(MCM)。核恐怖主义和核电站泄漏风险依然较高,可造成大面积急性辐射损伤。目前,可用于治疗急性放射综合征(ARS)的药物有限。人生长素释放肽是一种由 28 个氨基酸组成的肽激素,对多种身体系统具有广泛影响,包括内分泌、胃肠 (GI)、心血管和免疫系统。在我们已完成的 SBIR 第一阶段项目中,我们将大鼠和小鼠暴露于全身照射 (TBI),并证明从 TBI 后 24 小时开始皮下注射人生长素释放肽 6 天,显着提高了它们的存活率并减少了它们的体重减轻。我们进一步证明,在大鼠中,用人生长素释放肽治疗可以改善肠道完整性并减少肠道细胞凋亡和通透性。人类生长素释放肽可以大量合成以满足大规模紧急需求。此外,人类生长素释放肽已在多项针对其他疾病适应症的临床试验中进行了测试,具有出色的安全性。基于我们第一阶段的积极结果,我们假设人类生长素释放肽可以被开发为急性辐射损伤的有效暴露后缓解剂。在本提案中,我们将使用辐射损伤小鼠模型来鉴定人生长素释放肽的剂量修改因子(DMF)来治疗GI-ARS和造血ARS(H-ARS)。我们还将研究人类生长素释放肽减轻造血和胃肠道损伤的作用。此外,我们还将在非人类灵长类动物(NHP)中进行探索性研究,以评估人类生长素释放肽治疗对胃肠道和血液学对辐射暴露反应的影响。这些拟议的研究应该提供关于人生长素释放肽作为主要针对 GI-ARS 的新型辐射 MCM 的功效的重要信息。我们的最终目标是获得 FDA 批准,使用人生长素释放肽作为放射紧急情况后急性放射损伤患者的安全有效的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Weng-Lang Yang其他文献

Weng-Lang Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Weng-Lang Yang', 18)}}的其他基金

rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock
rhMFG-E8 作为失血性休克的有效辅助疗法
  • 批准号:
    9204427
  • 财政年份:
    2016
  • 资助金额:
    $ 98.25万
  • 项目类别:
A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury
一种新型重组蛋白可有效治疗急性肾损伤
  • 批准号:
    9314562
  • 财政年份:
    2016
  • 资助金额:
    $ 98.25万
  • 项目类别:
A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury
一种新型重组蛋白可有效治疗急性肾损伤
  • 批准号:
    9202013
  • 财政年份:
    2016
  • 资助金额:
    $ 98.25万
  • 项目类别:
Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly
人类生长素释放肽和生长激素治疗老年人脓毒症的临床前测试
  • 批准号:
    9346602
  • 财政年份:
    2014
  • 资助金额:
    $ 98.25万
  • 项目类别:
A Novel Recombinant Protein for Mitigating Total Body Radiation Injury
一种用于减轻全身辐射损伤的新型重组蛋白
  • 批准号:
    8781840
  • 财政年份:
    2014
  • 资助金额:
    $ 98.25万
  • 项目类别:
PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY
人类生长素释放肽和生长激素治疗老年脓毒症的临床前测试
  • 批准号:
    8714409
  • 财政年份:
    2014
  • 资助金额:
    $ 98.25万
  • 项目类别:
A Novel Recombinant Protein for Mitigating Total Body Radiation Injury
一种用于减轻全身辐射损伤的新型重组蛋白
  • 批准号:
    8865549
  • 财政年份:
    2014
  • 资助金额:
    $ 98.25万
  • 项目类别:
Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly
人类生长素释放肽和生长激素治疗老年人脓毒症的临床前测试
  • 批准号:
    9199963
  • 财政年份:
    2014
  • 资助金额:
    $ 98.25万
  • 项目类别:
Human Ghrelin As An Effective Mitigator of Acute Radiation Injury
人类生长素释放肽作为急性辐射损伤的有效缓解剂
  • 批准号:
    8198739
  • 财政年份:
    2011
  • 资助金额:
    $ 98.25万
  • 项目类别:
Human Ghrelin As An Effective Mitigator of Acute Radiation Injury
人类生长素释放肽作为急性辐射损伤的有效缓解剂
  • 批准号:
    8303441
  • 财政年份:
    2011
  • 资助金额:
    $ 98.25万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 98.25万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了